Market News & Trends
Scholar Rock Announces $36-Million Financing
Scholar Rock recently announced a $36-million Series B financing. Fidelity Management and Research Company led the financing with participation from additional new investor Cormorant Asset…
Genomics & Vertex Collaborate to Identify Target Therapeutic Pathways
Genomics plc recently announced that Vertex Pharmaceuticals will use Genomics’ integrated database and state-of-the-art analysis tools to inform its drug research and development. These tools…
Merus & Gustave Roussy Form Strategic Collaboration to Develop Innovative Bispecific Antibodies
Merus B.V. and Institut Gustave Roussy recently announced entry into a strategic collaboration to jointly develop bispecific antibodies for therapeutic immuno-oncology applications. Under the terms…
Lion Biotechnologies Submits INDA to Conduct Cancer Studies
Lion Biotechnologies, Inc. recently announced it has filed an INDA with the US FDA to conduct clinical trials of LN-145 in the treatment of cervical…
Fibrocell & Intrexon Announce Exclusive Channel Collaboration
Fibrocell Science, Inc. and Intrexon Corporation recently announced an Exclusive Channel Collaboration (ECC) for the development of genetically modified fibroblasts to treat chronic inflammatory and…
Cytokinetics Announces Start of Phase II Clinical Trial
Cytokinetics, Inc. recently announced that its first Phase II clinical trial of CK-2127107, a novel fast skeletal muscle troponin activator, in patients with spinal muscular…
Unilife Surges on Wearable Injector Devices Pact With Amgen
Unilife Corporation stock jumped more than 100% this morning after the company announced a new deal with Amgen to develop wearable injector devices. Pennsylvania-based Unilife…
US Demand for Drug Delivery Products to Reach $251 Billion
US Demand for Drug Delivery Products to Reach $251 Billion Demand for drug delivery products in the US is projected to increase 6.1%…
Haselmeier Self-Injection Devices Go Connected
Haselmeier has added connectivity to its devices portfolio with the announcement of its new Axis-D-Connect Disposable Pen Injector. Haselmeier has partnered with the Austrian Institute…
Nanosphere Announces $10-Million Registered Public Offering
Nanosphere, Inc. recently announced the pricing of a public offering of the company’s common stock with expected total gross proceeds of approximately $10 million. The…
Top Pharma Companies’ R&D Returns Continue to Slide
While the Research and Development (R&D) divisions of 12 leading pharmaceutical companies have progressed 306 assets into late-stage pipelines since 2010, with projected lifetime returns…
Abbott & UCSF Discover New Virus is Linked to Hepatitis C
Abbott and University of California San Francisco (UCSF) published research identifying a newly discovered human virus, known as human pegivirus 2 (HPgV-2), and proving it…
Neon Therapeutics & BMS Enter Clinical Trial Collaboration
Neon Therapeutics recently announced a clinical trial collaboration with Bristol-Myers Squibb. The collaboration will evaluate the combination of Neon Therapeutics’ proprietary personalized neoantigen vaccine, NEO-PV-01,…
Neovacs SA Signs Strategic Partnering Agreement With CKD Pharmaceutical
Neovacs recently announced the signature of an exclusive licensing agreement with Chong Kun Dang (CKD) Pharmaceutical Corp. (Seoul, South Korea) to market the IFNa-Kinoïd for…
Lightlake Therapeutics Receives Milestone Payment for Nasal Spray
Lightlake Therapeutics Inc. recently announced it has received a $2-million milestone payment from Adapt Pharma Limited. This milestone payment was triggered by the US FDA…
KemPharm Submits NDA for KP201/APAP & Requests Priority Review
KemPharm, Inc. recently announced it has submitted an NDA under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act for KP201/APAP to the US…
Egalet Submits NDA for Morphine Sulfate ER Tablets
Egalet Corporation recently announced the company has submitted an NDA for ARYMO ER (morphine sulfate) extended-release tablets for the management of pain severe enough to…
Pharmaceutical Deals Crucial to Offsetting $2.5-Billion Cost of Developing a Novel Drug
With the average cost of getting a novel drug to market at almost $2.5 billion, and few products achieving blockbuster status, deal-making is becoming increasingly…
Celldex Therapeutics Initiates Phase I/II Study
Celldex Therapeutics, Inc. recently announced the initiation of an open-label, Phase I/II safety and tolerability study examining the investigational combination of varlilumab and Roche's atezolizumab…
Soligenix Announces Initiation of Pivotal Phase III Clinical Trial
Soligenix, Inc. recently announced that patient enrollment has been opened for its Phase III, multicenter, randomized, double-blind, placebo-controlled study evaluating SGX301 (synthetic hypericin), as a…